nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—AHR—pancreatic cancer	0.439	1	CbGaD
Leflunomide—PTK2B—Sunitinib—pancreatic cancer	0.172	0.453	CbGbCtD
Leflunomide—ABCG2—Tamoxifen—pancreatic cancer	0.0291	0.0767	CbGbCtD
Leflunomide—ABCG2—Erlotinib—pancreatic cancer	0.0248	0.0652	CbGbCtD
Leflunomide—ABCG2—Irinotecan—pancreatic cancer	0.0224	0.0589	CbGbCtD
Leflunomide—ABCG2—Fluorouracil—pancreatic cancer	0.0215	0.0565	CbGbCtD
Leflunomide—ABCG2—Docetaxel—pancreatic cancer	0.0164	0.0432	CbGbCtD
Leflunomide—ABCG2—Sunitinib—pancreatic cancer	0.0163	0.043	CbGbCtD
Leflunomide—CYP1A2—Dacarbazine—pancreatic cancer	0.0151	0.0398	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—pancreatic cancer	0.0122	0.0322	CbGbCtD
Leflunomide—CYP1A2—Tamoxifen—pancreatic cancer	0.012	0.0316	CbGbCtD
Leflunomide—CYP2C9—Tamoxifen—pancreatic cancer	0.0108	0.0285	CbGbCtD
Leflunomide—CYP1A2—Erlotinib—pancreatic cancer	0.0102	0.0269	CbGbCtD
Leflunomide—CYP1A2—Fluorouracil—pancreatic cancer	0.00885	0.0233	CbGbCtD
Leflunomide—CYP2C9—Fluorouracil—pancreatic cancer	0.00798	0.021	CbGbCtD
Leflunomide—Niflumic Acid—PTGS2—pancreatic cancer	0.000446	1	CrCbGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NRAS—pancreatic cancer	7.63e-05	0.00126	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CD44—pancreatic cancer	7.63e-05	0.00126	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—STAT3—pancreatic cancer	7.59e-05	0.00126	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—NRAS—pancreatic cancer	7.57e-05	0.00125	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—AKT1—pancreatic cancer	7.53e-05	0.00125	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—AKT1—pancreatic cancer	7.53e-05	0.00125	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—CTNNB1—pancreatic cancer	7.51e-05	0.00124	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—SRC—pancreatic cancer	7.49e-05	0.00124	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—AKT1—pancreatic cancer	7.44e-05	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—AKT1—pancreatic cancer	7.34e-05	0.00122	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	7.32e-05	0.00121	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—PIK3CA—pancreatic cancer	7.32e-05	0.00121	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GCG—pancreatic cancer	7.32e-05	0.00121	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—pancreatic cancer	7.29e-05	0.00121	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—NRAS—pancreatic cancer	7.2e-05	0.00119	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CASP3—pancreatic cancer	7.18e-05	0.00119	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—pancreatic cancer	7.08e-05	0.00117	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—pancreatic cancer	6.95e-05	0.00115	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CTNNB1—pancreatic cancer	6.92e-05	0.00115	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	6.9e-05	0.00114	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—STK11—pancreatic cancer	6.88e-05	0.00114	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AKT1—pancreatic cancer	6.82e-05	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—SRC—pancreatic cancer	6.79e-05	0.00112	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—KRAS—pancreatic cancer	6.57e-05	0.00109	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—KRAS—pancreatic cancer	6.52e-05	0.00108	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—pancreatic cancer	6.42e-05	0.00106	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—pancreatic cancer	6.41e-05	0.00106	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	6.26e-05	0.00104	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—SRC—pancreatic cancer	6.25e-05	0.00104	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—KRAS—pancreatic cancer	6.2e-05	0.00103	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—pancreatic cancer	6.17e-05	0.00102	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PTEN—pancreatic cancer	6.14e-05	0.00102	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNA5—pancreatic cancer	6.07e-05	0.001	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—PIK3CA—pancreatic cancer	6.03e-05	0.000999	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—STAT3—pancreatic cancer	6.03e-05	0.000998	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—PIK3CA—pancreatic cancer	5.99e-05	0.000991	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—AKT1—pancreatic cancer	5.98e-05	0.00099	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—TYMS—pancreatic cancer	5.92e-05	0.000979	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—DTX4—pancreatic cancer	5.89e-05	0.000975	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PPP2R5B—pancreatic cancer	5.73e-05	0.000949	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—PIK3CA—pancreatic cancer	5.7e-05	0.000943	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—SRC—pancreatic cancer	5.69e-05	0.000942	CbGpPWpGaD
Leflunomide—Angina pectoris—Doxorubicin—pancreatic cancer	5.67e-05	0.00047	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—AKT1—pancreatic cancer	5.66e-05	0.000937	CbGpPWpGaD
Leflunomide—Hypersensitivity—Irinotecan—pancreatic cancer	5.65e-05	0.000469	CcSEcCtD
Leflunomide—Pneumonia—Epirubicin—pancreatic cancer	5.64e-05	0.000468	CcSEcCtD
Leflunomide—Hypertension—Docetaxel—pancreatic cancer	5.61e-05	0.000465	CcSEcCtD
Leflunomide—Infestation—Epirubicin—pancreatic cancer	5.61e-05	0.000465	CcSEcCtD
Leflunomide—Infestation NOS—Epirubicin—pancreatic cancer	5.61e-05	0.000465	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—pancreatic cancer	5.6e-05	0.000464	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—pancreatic cancer	5.58e-05	0.000924	CbGpPWpGaD
Leflunomide—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	5.56e-05	0.000461	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—pancreatic cancer	5.54e-05	0.000917	CbGpPWpGaD
Leflunomide—Myalgia—Docetaxel—pancreatic cancer	5.53e-05	0.000459	CcSEcCtD
Leflunomide—Chest pain—Docetaxel—pancreatic cancer	5.53e-05	0.000459	CcSEcCtD
Leflunomide—Arthralgia—Docetaxel—pancreatic cancer	5.53e-05	0.000459	CcSEcCtD
Leflunomide—Nausea—Sunitinib—pancreatic cancer	5.53e-05	0.000459	CcSEcCtD
Leflunomide—Pancytopenia—Doxorubicin—pancreatic cancer	5.53e-05	0.000458	CcSEcCtD
Leflunomide—Renal failure—Epirubicin—pancreatic cancer	5.52e-05	0.000457	CcSEcCtD
Leflunomide—Asthenia—Irinotecan—pancreatic cancer	5.51e-05	0.000457	CcSEcCtD
Leflunomide—Neuropathy peripheral—Epirubicin—pancreatic cancer	5.5e-05	0.000456	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	5.5e-05	0.000456	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—STAT3—pancreatic cancer	5.49e-05	0.000909	CbGpPWpGaD
Leflunomide—Stomatitis—Epirubicin—pancreatic cancer	5.47e-05	0.000453	CcSEcCtD
Leflunomide—Jaundice—Epirubicin—pancreatic cancer	5.47e-05	0.000453	CcSEcCtD
Leflunomide—Conjunctivitis—Epirubicin—pancreatic cancer	5.45e-05	0.000452	CcSEcCtD
Leflunomide—Urinary tract infection—Epirubicin—pancreatic cancer	5.45e-05	0.000452	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—pancreatic cancer	5.44e-05	0.000451	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—pancreatic cancer	5.44e-05	0.000451	CcSEcCtD
Leflunomide—Hypersensitivity—Fluorouracil—pancreatic cancer	5.42e-05	0.000449	CcSEcCtD
Leflunomide—Dry mouth—Docetaxel—pancreatic cancer	5.41e-05	0.000449	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	5.41e-05	0.000449	CcSEcCtD
Leflunomide—Pollakiuria—Doxorubicin—pancreatic cancer	5.38e-05	0.000446	CcSEcCtD
Leflunomide—Asthenia—Gemcitabine—pancreatic cancer	5.36e-05	0.000445	CcSEcCtD
Leflunomide—Haematuria—Epirubicin—pancreatic cancer	5.35e-05	0.000444	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PRLHR—pancreatic cancer	5.35e-05	0.000885	CbGpPWpGaD
Leflunomide—Hepatobiliary disease—Epirubicin—pancreatic cancer	5.31e-05	0.00044	CcSEcCtD
Leflunomide—Anaphylactic shock—Docetaxel—pancreatic cancer	5.31e-05	0.00044	CcSEcCtD
Leflunomide—Epistaxis—Epirubicin—pancreatic cancer	5.29e-05	0.000439	CcSEcCtD
Leflunomide—Pruritus—Gemcitabine—pancreatic cancer	5.29e-05	0.000439	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—pancreatic cancer	5.29e-05	0.000875	CbGpPWpGaD
Leflunomide—Infection—Docetaxel—pancreatic cancer	5.27e-05	0.000437	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—pancreatic cancer	5.27e-05	0.000872	CbGpPWpGaD
Leflunomide—Weight decreased—Doxorubicin—pancreatic cancer	5.27e-05	0.000437	CcSEcCtD
Leflunomide—Sinusitis—Epirubicin—pancreatic cancer	5.26e-05	0.000436	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CD—pancreatic cancer	5.26e-05	0.000871	CbGpPWpGaD
Leflunomide—Hyperglycaemia—Doxorubicin—pancreatic cancer	5.25e-05	0.000436	CcSEcCtD
Leflunomide—Diarrhoea—Irinotecan—pancreatic cancer	5.25e-05	0.000435	CcSEcCtD
Leflunomide—Agranulocytosis—Epirubicin—pancreatic cancer	5.24e-05	0.000434	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—pancreatic cancer	5.22e-05	0.000433	CcSEcCtD
Leflunomide—Nervous system disorder—Docetaxel—pancreatic cancer	5.2e-05	0.000431	CcSEcCtD
Leflunomide—Pruritus—Fluorouracil—pancreatic cancer	5.2e-05	0.000431	CcSEcCtD
Leflunomide—Thrombocytopenia—Docetaxel—pancreatic cancer	5.19e-05	0.000431	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—pancreatic cancer	5.19e-05	0.00043	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—pancreatic cancer	5.19e-05	0.00043	CcSEcCtD
Leflunomide—Tachycardia—Docetaxel—pancreatic cancer	5.18e-05	0.000429	CcSEcCtD
Leflunomide—PTK2B—Cell-Cell communication—PIK3CA—pancreatic cancer	5.16e-05	0.000855	CbGpPWpGaD
Leflunomide—Skin disorder—Docetaxel—pancreatic cancer	5.15e-05	0.000427	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	5.15e-05	0.000427	CcSEcCtD
Leflunomide—Diarrhoea—Gemcitabine—pancreatic cancer	5.12e-05	0.000424	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—pancreatic cancer	5.1e-05	0.000423	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—pancreatic cancer	5.09e-05	0.000422	CcSEcCtD
Leflunomide—Dizziness—Irinotecan—pancreatic cancer	5.08e-05	0.000421	CcSEcCtD
Leflunomide—Haemoglobin—Epirubicin—pancreatic cancer	5.06e-05	0.00042	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—pancreatic cancer	5.06e-05	0.00042	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—pancreatic cancer	5.06e-05	0.00042	CcSEcCtD
Leflunomide—Anorexia—Docetaxel—pancreatic cancer	5.06e-05	0.000419	CcSEcCtD
Leflunomide—Rhinitis—Epirubicin—pancreatic cancer	5.05e-05	0.000419	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—pancreatic cancer	5.05e-05	0.000418	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—pancreatic cancer	5.05e-05	0.000418	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—pancreatic cancer	5.04e-05	0.000418	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—pancreatic cancer	5.04e-05	0.000418	CcSEcCtD
Leflunomide—Diarrhoea—Fluorouracil—pancreatic cancer	5.03e-05	0.000417	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—ZNRF3—pancreatic cancer	5.03e-05	0.000832	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ACVR1B—pancreatic cancer	5.03e-05	0.000832	CbGpPWpGaD
Leflunomide—Pharyngitis—Epirubicin—pancreatic cancer	5e-05	0.000415	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—pancreatic cancer	4.99e-05	0.000826	CbGpPWpGaD
Leflunomide—Urinary tract disorder—Epirubicin—pancreatic cancer	4.97e-05	0.000412	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—pancreatic cancer	4.96e-05	0.000411	CcSEcCtD
Leflunomide—Hypotension—Docetaxel—pancreatic cancer	4.96e-05	0.000411	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—pancreatic cancer	4.95e-05	0.00041	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—pancreatic cancer	4.95e-05	0.00041	CcSEcCtD
Leflunomide—Urethral disorder—Epirubicin—pancreatic cancer	4.94e-05	0.000409	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—AKT1—pancreatic cancer	4.93e-05	0.000816	CbGpPWpGaD
Leflunomide—Hepatobiliary disease—Doxorubicin—pancreatic cancer	4.91e-05	0.000407	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—pancreatic cancer	4.9e-05	0.000406	CcSEcCtD
Leflunomide—Vomiting—Irinotecan—pancreatic cancer	4.88e-05	0.000405	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—pancreatic cancer	4.87e-05	0.000404	CcSEcCtD
Leflunomide—Dizziness—Fluorouracil—pancreatic cancer	4.86e-05	0.000403	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—pancreatic cancer	4.84e-05	0.000402	CcSEcCtD
Leflunomide—Rash—Irinotecan—pancreatic cancer	4.84e-05	0.000401	CcSEcCtD
Leflunomide—Dermatitis—Irinotecan—pancreatic cancer	4.83e-05	0.000401	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	4.83e-05	0.000401	CcSEcCtD
Leflunomide—DHODH—Metabolism—APOE—pancreatic cancer	4.81e-05	0.000797	CbGpPWpGaD
Leflunomide—Headache—Irinotecan—pancreatic cancer	4.81e-05	0.000399	CcSEcCtD
Leflunomide—Insomnia—Docetaxel—pancreatic cancer	4.8e-05	0.000398	CcSEcCtD
Leflunomide—Paraesthesia—Docetaxel—pancreatic cancer	4.76e-05	0.000395	CcSEcCtD
Leflunomide—Erythema multiforme—Epirubicin—pancreatic cancer	4.76e-05	0.000395	CcSEcCtD
Leflunomide—Vomiting—Gemcitabine—pancreatic cancer	4.75e-05	0.000394	CcSEcCtD
Leflunomide—Dyspnoea—Docetaxel—pancreatic cancer	4.73e-05	0.000392	CcSEcCtD
Leflunomide—Rash—Gemcitabine—pancreatic cancer	4.71e-05	0.000391	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—pancreatic cancer	4.71e-05	0.00078	CbGpPWpGaD
Leflunomide—Dermatitis—Gemcitabine—pancreatic cancer	4.71e-05	0.00039	CcSEcCtD
Leflunomide—Eye disorder—Epirubicin—pancreatic cancer	4.71e-05	0.00039	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	4.7e-05	0.000779	CbGpPWpGaD
Leflunomide—Haemoglobin—Doxorubicin—pancreatic cancer	4.68e-05	0.000388	CcSEcCtD
Leflunomide—Headache—Gemcitabine—pancreatic cancer	4.68e-05	0.000388	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—pancreatic cancer	4.67e-05	0.000388	CcSEcCtD
Leflunomide—Vomiting—Fluorouracil—pancreatic cancer	4.67e-05	0.000388	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—pancreatic cancer	4.67e-05	0.000387	CcSEcCtD
Leflunomide—Dyspepsia—Docetaxel—pancreatic cancer	4.67e-05	0.000387	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—pancreatic cancer	4.66e-05	0.000386	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—pancreatic cancer	4.66e-05	0.000386	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—pancreatic cancer	4.65e-05	0.00077	CbGpPWpGaD
Leflunomide—Rash—Fluorouracil—pancreatic cancer	4.63e-05	0.000384	CcSEcCtD
Leflunomide—Dermatitis—Fluorouracil—pancreatic cancer	4.63e-05	0.000384	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—pancreatic cancer	4.63e-05	0.000384	CcSEcCtD
Leflunomide—Decreased appetite—Docetaxel—pancreatic cancer	4.61e-05	0.000382	CcSEcCtD
Leflunomide—Headache—Fluorouracil—pancreatic cancer	4.61e-05	0.000382	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—pancreatic cancer	4.6e-05	0.000382	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—pancreatic cancer	4.59e-05	0.000381	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CB—pancreatic cancer	4.58e-05	0.000759	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	4.58e-05	0.00038	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—pancreatic cancer	4.58e-05	0.00038	CcSEcCtD
Leflunomide—Fatigue—Docetaxel—pancreatic cancer	4.57e-05	0.000379	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—pancreatic cancer	4.57e-05	0.000379	CcSEcCtD
Leflunomide—Nausea—Irinotecan—pancreatic cancer	4.56e-05	0.000378	CcSEcCtD
Leflunomide—Immune system disorder—Epirubicin—pancreatic cancer	4.55e-05	0.000377	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SSTR3—pancreatic cancer	4.55e-05	0.000753	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—DTX1—pancreatic cancer	4.55e-05	0.000753	CbGpPWpGaD
Leflunomide—Mediastinal disorder—Epirubicin—pancreatic cancer	4.54e-05	0.000376	CcSEcCtD
Leflunomide—Pain—Docetaxel—pancreatic cancer	4.54e-05	0.000376	CcSEcCtD
Leflunomide—Constipation—Docetaxel—pancreatic cancer	4.54e-05	0.000376	CcSEcCtD
Leflunomide—Chills—Epirubicin—pancreatic cancer	4.52e-05	0.000375	CcSEcCtD
Leflunomide—Arrhythmia—Epirubicin—pancreatic cancer	4.5e-05	0.000373	CcSEcCtD
Leflunomide—Alopecia—Epirubicin—pancreatic cancer	4.45e-05	0.000369	CcSEcCtD
Leflunomide—Nausea—Gemcitabine—pancreatic cancer	4.44e-05	0.000368	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—pancreatic cancer	4.41e-05	0.000366	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—pancreatic cancer	4.41e-05	0.000365	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—pancreatic cancer	4.4e-05	0.000729	CbGpPWpGaD
Leflunomide—Malnutrition—Epirubicin—pancreatic cancer	4.38e-05	0.000364	CcSEcCtD
Leflunomide—Feeling abnormal—Docetaxel—pancreatic cancer	4.37e-05	0.000363	CcSEcCtD
Leflunomide—Nausea—Fluorouracil—pancreatic cancer	4.37e-05	0.000362	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SSTR1—pancreatic cancer	4.36e-05	0.000722	CbGpPWpGaD
Leflunomide—Eye disorder—Doxorubicin—pancreatic cancer	4.36e-05	0.000361	CcSEcCtD
Leflunomide—DHODH—Metabolism—PIK3CG—pancreatic cancer	4.34e-05	0.000719	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.34e-05	0.00036	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—pancreatic cancer	4.33e-05	0.000359	CcSEcCtD
Leflunomide—Flatulence—Epirubicin—pancreatic cancer	4.32e-05	0.000358	CcSEcCtD
Leflunomide—Dysgeusia—Epirubicin—pancreatic cancer	4.29e-05	0.000356	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PPY—pancreatic cancer	4.27e-05	0.000708	CbGpPWpGaD
Leflunomide—Back pain—Epirubicin—pancreatic cancer	4.24e-05	0.000352	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—pancreatic cancer	4.23e-05	0.000701	CbGpPWpGaD
Leflunomide—Muscle spasms—Epirubicin—pancreatic cancer	4.22e-05	0.00035	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—pancreatic cancer	4.21e-05	0.000349	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—pancreatic cancer	4.2e-05	0.000348	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SSTR2—pancreatic cancer	4.2e-05	0.000695	CbGpPWpGaD
Leflunomide—Abdominal pain—Docetaxel—pancreatic cancer	4.19e-05	0.000348	CcSEcCtD
Leflunomide—Body temperature increased—Docetaxel—pancreatic cancer	4.19e-05	0.000348	CcSEcCtD
Leflunomide—DHODH—Metabolism—PPARG—pancreatic cancer	4.19e-05	0.000694	CbGpPWpGaD
Leflunomide—Chills—Doxorubicin—pancreatic cancer	4.18e-05	0.000347	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—pancreatic cancer	4.16e-05	0.000345	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—pancreatic cancer	4.13e-05	0.000343	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—pancreatic cancer	4.12e-05	0.000341	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—pancreatic cancer	4.08e-05	0.000339	CcSEcCtD
Leflunomide—Ill-defined disorder—Epirubicin—pancreatic cancer	4.07e-05	0.000337	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—pancreatic cancer	4.06e-05	0.000336	CcSEcCtD
Leflunomide—Anaemia—Epirubicin—pancreatic cancer	4.05e-05	0.000336	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CCKBR—pancreatic cancer	4.05e-05	0.000671	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—pancreatic cancer	4.01e-05	0.000663	CbGpPWpGaD
Leflunomide—Flatulence—Doxorubicin—pancreatic cancer	4e-05	0.000331	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—pancreatic cancer	3.97e-05	0.000329	CcSEcCtD
Leflunomide—Malaise—Epirubicin—pancreatic cancer	3.95e-05	0.000328	CcSEcCtD
Leflunomide—Vertigo—Epirubicin—pancreatic cancer	3.94e-05	0.000327	CcSEcCtD
Leflunomide—Leukopenia—Epirubicin—pancreatic cancer	3.92e-05	0.000325	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—pancreatic cancer	3.92e-05	0.000325	CcSEcCtD
Leflunomide—Hypersensitivity—Docetaxel—pancreatic cancer	3.91e-05	0.000324	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—pancreatic cancer	3.9e-05	0.000323	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—pancreatic cancer	3.89e-05	0.000643	CbGpPWpGaD
Leflunomide—Palpitations—Epirubicin—pancreatic cancer	3.87e-05	0.000321	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—pancreatic cancer	3.87e-05	0.00064	CbGpPWpGaD
Leflunomide—Cough—Epirubicin—pancreatic cancer	3.83e-05	0.000317	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—pancreatic cancer	3.82e-05	0.000317	CcSEcCtD
Leflunomide—DHODH—Metabolism—PIK3CD—pancreatic cancer	3.82e-05	0.000632	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GLI1—pancreatic cancer	3.81e-05	0.000631	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—DTX4—pancreatic cancer	3.81e-05	0.000631	CbGpPWpGaD
Leflunomide—Asthenia—Docetaxel—pancreatic cancer	3.81e-05	0.000316	CcSEcCtD
Leflunomide—Hypertension—Epirubicin—pancreatic cancer	3.79e-05	0.000314	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—pancreatic cancer	3.76e-05	0.000312	CcSEcCtD
Leflunomide—Pruritus—Docetaxel—pancreatic cancer	3.75e-05	0.000311	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—pancreatic cancer	3.75e-05	0.000311	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—pancreatic cancer	3.73e-05	0.00031	CcSEcCtD
Leflunomide—Myalgia—Epirubicin—pancreatic cancer	3.73e-05	0.00031	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—pancreatic cancer	3.73e-05	0.00031	CcSEcCtD
Leflunomide—Anxiety—Epirubicin—pancreatic cancer	3.72e-05	0.000308	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	3.71e-05	0.000307	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PPP2R5B—pancreatic cancer	3.71e-05	0.000613	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRP1—pancreatic cancer	3.71e-05	0.000613	CbGpPWpGaD
Leflunomide—Discomfort—Epirubicin—pancreatic cancer	3.69e-05	0.000306	CcSEcCtD
Leflunomide—Malaise—Doxorubicin—pancreatic cancer	3.66e-05	0.000303	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—pancreatic cancer	3.65e-05	0.000303	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—pancreatic cancer	3.65e-05	0.000302	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—pancreatic cancer	3.63e-05	0.000301	CcSEcCtD
Leflunomide—Diarrhoea—Docetaxel—pancreatic cancer	3.63e-05	0.000301	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—pancreatic cancer	3.62e-05	0.000599	CbGpPWpGaD
Leflunomide—Palpitations—Doxorubicin—pancreatic cancer	3.59e-05	0.000297	CcSEcCtD
Leflunomide—Anaphylactic shock—Epirubicin—pancreatic cancer	3.58e-05	0.000297	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—HEY2—pancreatic cancer	3.57e-05	0.000591	CbGpPWpGaD
Leflunomide—Infection—Epirubicin—pancreatic cancer	3.56e-05	0.000295	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—STAT3—pancreatic cancer	3.54e-05	0.000587	CbGpPWpGaD
Leflunomide—Cough—Doxorubicin—pancreatic cancer	3.54e-05	0.000294	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—pancreatic cancer	3.54e-05	0.000586	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NRAS—pancreatic cancer	3.53e-05	0.000585	CbGpPWpGaD
Leflunomide—Nervous system disorder—Epirubicin—pancreatic cancer	3.51e-05	0.000291	CcSEcCtD
Leflunomide—Dizziness—Docetaxel—pancreatic cancer	3.51e-05	0.000291	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—pancreatic cancer	3.5e-05	0.000291	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—pancreatic cancer	3.5e-05	0.00029	CcSEcCtD
Leflunomide—Tachycardia—Epirubicin—pancreatic cancer	3.49e-05	0.00029	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GAST—pancreatic cancer	3.48e-05	0.000577	CbGpPWpGaD
Leflunomide—Skin disorder—Epirubicin—pancreatic cancer	3.48e-05	0.000288	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—pancreatic cancer	3.46e-05	0.000287	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—pancreatic cancer	3.45e-05	0.000286	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—pancreatic cancer	3.45e-05	0.000286	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—pancreatic cancer	3.45e-05	0.000286	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—pancreatic cancer	3.44e-05	0.000285	CcSEcCtD
Leflunomide—PTK2B—Immune System—CD44—pancreatic cancer	3.43e-05	0.000568	CbGpPWpGaD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.43e-05	0.000284	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—pancreatic cancer	3.41e-05	0.000283	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—pancreatic cancer	3.41e-05	0.000283	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	3.4e-05	0.000563	CbGpPWpGaD
Leflunomide—Dry mouth—Doxorubicin—pancreatic cancer	3.38e-05	0.00028	CcSEcCtD
Leflunomide—Vomiting—Docetaxel—pancreatic cancer	3.37e-05	0.00028	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	3.37e-05	0.000558	CbGpPWpGaD
Leflunomide—Rash—Docetaxel—pancreatic cancer	3.35e-05	0.000277	CcSEcCtD
Leflunomide—Hypotension—Epirubicin—pancreatic cancer	3.34e-05	0.000277	CcSEcCtD
Leflunomide—Dermatitis—Docetaxel—pancreatic cancer	3.34e-05	0.000277	CcSEcCtD
Leflunomide—DHODH—Metabolism—PIK3CB—pancreatic cancer	3.33e-05	0.000551	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNA1—pancreatic cancer	3.33e-05	0.000551	CbGpPWpGaD
Leflunomide—Headache—Docetaxel—pancreatic cancer	3.32e-05	0.000276	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.31e-05	0.000275	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SCT—pancreatic cancer	3.3e-05	0.000547	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HEY1—pancreatic cancer	3.3e-05	0.000547	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTGS2—pancreatic cancer	3.3e-05	0.000546	CbGpPWpGaD
Leflunomide—Infection—Doxorubicin—pancreatic cancer	3.29e-05	0.000273	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.26e-05	0.00027	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—pancreatic cancer	3.25e-05	0.000269	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.24e-05	0.000269	CcSEcCtD
Leflunomide—Insomnia—Epirubicin—pancreatic cancer	3.24e-05	0.000268	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—pancreatic cancer	3.23e-05	0.000268	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—pancreatic cancer	3.22e-05	0.000267	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—pancreatic cancer	3.21e-05	0.000266	CcSEcCtD
Leflunomide—Hyperhidrosis—Doxorubicin—pancreatic cancer	3.2e-05	0.000265	CcSEcCtD
Leflunomide—Dyspnoea—Epirubicin—pancreatic cancer	3.19e-05	0.000265	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—pancreatic cancer	3.16e-05	0.000262	CcSEcCtD
Leflunomide—Nausea—Docetaxel—pancreatic cancer	3.15e-05	0.000261	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CCK—pancreatic cancer	3.15e-05	0.000522	CbGpPWpGaD
Leflunomide—Dyspepsia—Epirubicin—pancreatic cancer	3.15e-05	0.000261	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	3.13e-05	0.000518	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	3.13e-05	0.000518	CbGpPWpGaD
Leflunomide—Decreased appetite—Epirubicin—pancreatic cancer	3.11e-05	0.000258	CcSEcCtD
Leflunomide—PTK2B—Immune System—IFNA2—pancreatic cancer	3.1e-05	0.000512	CbGpPWpGaD
Leflunomide—Hypotension—Doxorubicin—pancreatic cancer	3.09e-05	0.000257	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.09e-05	0.000256	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—pancreatic cancer	3.09e-05	0.000256	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GLP1R—pancreatic cancer	3.07e-05	0.000508	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CNR2—pancreatic cancer	3.07e-05	0.000508	CbGpPWpGaD
Leflunomide—Constipation—Epirubicin—pancreatic cancer	3.06e-05	0.000254	CcSEcCtD
Leflunomide—Pain—Epirubicin—pancreatic cancer	3.06e-05	0.000254	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	3.05e-05	0.000504	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—pancreatic cancer	3.04e-05	0.000504	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCKAR—pancreatic cancer	3.02e-05	0.0005	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.02e-05	0.00025	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	3.01e-05	0.000498	CbGpPWpGaD
Leflunomide—Insomnia—Doxorubicin—pancreatic cancer	2.99e-05	0.000248	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—pancreatic cancer	2.97e-05	0.000247	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—pancreatic cancer	2.95e-05	0.000245	CcSEcCtD
Leflunomide—Feeling abnormal—Epirubicin—pancreatic cancer	2.95e-05	0.000245	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—JAG2—pancreatic cancer	2.93e-05	0.000485	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.93e-05	0.000243	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—pancreatic cancer	2.91e-05	0.000242	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—MEN1—pancreatic cancer	2.89e-05	0.000478	CbGpPWpGaD
Leflunomide—Decreased appetite—Doxorubicin—pancreatic cancer	2.88e-05	0.000239	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTEN—pancreatic cancer	2.88e-05	0.000476	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.86e-05	0.000237	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—pancreatic cancer	2.85e-05	0.000237	CcSEcCtD
Leflunomide—Urticaria—Epirubicin—pancreatic cancer	2.84e-05	0.000236	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—pancreatic cancer	2.83e-05	0.000235	CcSEcCtD
Leflunomide—Pain—Doxorubicin—pancreatic cancer	2.83e-05	0.000235	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—pancreatic cancer	2.83e-05	0.000235	CcSEcCtD
Leflunomide—Body temperature increased—Epirubicin—pancreatic cancer	2.83e-05	0.000235	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	2.8e-05	0.000464	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	2.8e-05	0.000463	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—pancreatic cancer	2.79e-05	0.000463	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PRSS1—pancreatic cancer	2.79e-05	0.000463	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SHH—pancreatic cancer	2.75e-05	0.000456	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	2.74e-05	0.000454	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	2.74e-05	0.000454	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH4—pancreatic cancer	2.74e-05	0.000453	CbGpPWpGaD
Leflunomide—Feeling abnormal—Doxorubicin—pancreatic cancer	2.73e-05	0.000226	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—IAPP—pancreatic cancer	2.72e-05	0.00045	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.71e-05	0.000225	CcSEcCtD
Leflunomide—Hypersensitivity—Epirubicin—pancreatic cancer	2.64e-05	0.000219	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—pancreatic cancer	2.63e-05	0.000218	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—pancreatic cancer	2.62e-05	0.000217	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—pancreatic cancer	2.62e-05	0.000217	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PTHLH—pancreatic cancer	2.61e-05	0.000432	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTCH1—pancreatic cancer	2.61e-05	0.000432	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	2.61e-05	0.000432	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	2.61e-05	0.000432	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	2.59e-05	0.000429	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—pancreatic cancer	2.59e-05	0.000428	CbGpPWpGaD
Leflunomide—Asthenia—Epirubicin—pancreatic cancer	2.57e-05	0.000213	CcSEcCtD
Leflunomide—Pruritus—Epirubicin—pancreatic cancer	2.53e-05	0.00021	CcSEcCtD
Leflunomide—Diarrhoea—Epirubicin—pancreatic cancer	2.45e-05	0.000203	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—pancreatic cancer	2.44e-05	0.000202	CcSEcCtD
Leflunomide—ABCG2—Metabolism—ARG2—pancreatic cancer	2.42e-05	0.000401	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SST—pancreatic cancer	2.39e-05	0.000395	CbGpPWpGaD
Leflunomide—Asthenia—Doxorubicin—pancreatic cancer	2.38e-05	0.000197	CcSEcCtD
Leflunomide—Dizziness—Epirubicin—pancreatic cancer	2.37e-05	0.000196	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—pancreatic cancer	2.34e-05	0.000194	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—JAG1—pancreatic cancer	2.34e-05	0.000387	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH3—pancreatic cancer	2.33e-05	0.000385	CbGpPWpGaD
Leflunomide—Vomiting—Epirubicin—pancreatic cancer	2.28e-05	0.000189	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—pancreatic cancer	2.27e-05	0.000188	CcSEcCtD
Leflunomide—Rash—Epirubicin—pancreatic cancer	2.26e-05	0.000187	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—pancreatic cancer	2.25e-05	0.000187	CcSEcCtD
Leflunomide—Headache—Epirubicin—pancreatic cancer	2.24e-05	0.000186	CcSEcCtD
Leflunomide—PTK2B—Immune System—BCL2L1—pancreatic cancer	2.23e-05	0.000369	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TSC2—pancreatic cancer	2.21e-05	0.000366	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CNR1—pancreatic cancer	2.2e-05	0.000365	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	2.2e-05	0.000364	CbGpPWpGaD
Leflunomide—Dizziness—Doxorubicin—pancreatic cancer	2.19e-05	0.000182	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GCG—pancreatic cancer	2.13e-05	0.000352	CbGpPWpGaD
Leflunomide—Nausea—Epirubicin—pancreatic cancer	2.13e-05	0.000176	CcSEcCtD
Leflunomide—ABCG2—Metabolism—TYMP—pancreatic cancer	2.12e-05	0.000351	CbGpPWpGaD
Leflunomide—Vomiting—Doxorubicin—pancreatic cancer	2.11e-05	0.000175	CcSEcCtD
Leflunomide—Rash—Doxorubicin—pancreatic cancer	2.09e-05	0.000173	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—pancreatic cancer	2.09e-05	0.000173	CcSEcCtD
Leflunomide—Headache—Doxorubicin—pancreatic cancer	2.07e-05	0.000172	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—AGTR1—pancreatic cancer	2.03e-05	0.000336	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CA—pancreatic cancer	2.03e-05	0.000336	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NFKBIA—pancreatic cancer	2.02e-05	0.000334	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STK11—pancreatic cancer	2e-05	0.000331	CbGpPWpGaD
Leflunomide—Nausea—Doxorubicin—pancreatic cancer	1.97e-05	0.000163	CcSEcCtD
Leflunomide—PTK2B—Immune System—EGF—pancreatic cancer	1.93e-05	0.00032	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—pancreatic cancer	1.8e-05	0.000298	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SMAD4—pancreatic cancer	1.75e-05	0.00029	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CD—pancreatic cancer	1.72e-05	0.000284	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HES1—pancreatic cancer	1.71e-05	0.000283	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GLP1R—pancreatic cancer	1.71e-05	0.000283	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—DPYD—pancreatic cancer	1.68e-05	0.000278	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—pancreatic cancer	1.66e-05	0.000274	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC2A2—pancreatic cancer	1.59e-05	0.000264	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—pancreatic cancer	1.5e-05	0.000248	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CB—pancreatic cancer	1.5e-05	0.000248	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIF1A—pancreatic cancer	1.43e-05	0.000237	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TSC2—pancreatic cancer	1.43e-05	0.000237	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PRSS1—pancreatic cancer	1.41e-05	0.000234	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APOE—pancreatic cancer	1.4e-05	0.000232	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KDR—pancreatic cancer	1.37e-05	0.000227	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—pancreatic cancer	1.33e-05	0.00022	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NFKBIA—pancreatic cancer	1.3e-05	0.000216	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—pancreatic cancer	1.29e-05	0.000214	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH1—pancreatic cancer	1.29e-05	0.000214	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CG—pancreatic cancer	1.26e-05	0.000209	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGF—pancreatic cancer	1.25e-05	0.000207	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CD44—pancreatic cancer	1.23e-05	0.000204	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ARG2—pancreatic cancer	1.22e-05	0.000203	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PRSS1—pancreatic cancer	1.21e-05	0.0002	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—SRC—pancreatic cancer	1.2e-05	0.000199	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GCG—pancreatic cancer	1.18e-05	0.000196	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—pancreatic cancer	1.16e-05	0.000192	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—pancreatic cancer	1.15e-05	0.000191	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—STK11—pancreatic cancer	1.11e-05	0.000184	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CD—pancreatic cancer	1.11e-05	0.000184	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMP—pancreatic cancer	1.07e-05	0.000177	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—pancreatic cancer	1.05e-05	0.000174	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ARG2—pancreatic cancer	1.05e-05	0.000173	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—pancreatic cancer	9.94e-06	0.000164	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CB—pancreatic cancer	9.68e-06	0.00016	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TYMS—pancreatic cancer	9.57e-06	0.000158	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—pancreatic cancer	9.3e-06	0.000154	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMP—pancreatic cancer	9.14e-06	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—pancreatic cancer	9.13e-06	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—pancreatic cancer	8.9e-06	0.000147	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	8.83e-06	0.000146	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—pancreatic cancer	8.67e-06	0.000143	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GLP1R—pancreatic cancer	8.62e-06	0.000143	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—pancreatic cancer	8.58e-06	0.000142	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—DPYD—pancreatic cancer	8.48e-06	0.00014	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—pancreatic cancer	8.45e-06	0.00014	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—pancreatic cancer	8.41e-06	0.000139	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—pancreatic cancer	8.37e-06	0.000138	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	8.05e-06	0.000133	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	7.97e-06	0.000132	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOE—pancreatic cancer	7.78e-06	0.000129	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SRC—pancreatic cancer	7.76e-06	0.000128	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.69e-06	0.000127	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—pancreatic cancer	7.56e-06	0.000125	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.54e-06	0.000125	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—pancreatic cancer	7.48e-06	0.000124	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—pancreatic cancer	7.46e-06	0.000124	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—pancreatic cancer	7.46e-06	0.000123	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GLP1R—pancreatic cancer	7.37e-06	0.000122	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—DPYD—pancreatic cancer	7.25e-06	0.00012	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CG—pancreatic cancer	7.02e-06	0.000116	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	7e-06	0.000116	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—pancreatic cancer	6.95e-06	0.000115	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—pancreatic cancer	6.94e-06	0.000115	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	6.88e-06	0.000114	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.81e-06	0.000113	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—pancreatic cancer	6.8e-06	0.000113	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—pancreatic cancer	6.78e-06	0.000112	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.57e-06	0.000109	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—pancreatic cancer	6.42e-06	0.000106	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CD44—pancreatic cancer	6.23e-06	0.000103	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CD—pancreatic cancer	6.18e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.1e-06	0.000101	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.05e-06	0.0001	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.98e-06	9.91e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GCG—pancreatic cancer	5.98e-06	9.89e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—pancreatic cancer	5.9e-06	9.77e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—pancreatic cancer	5.71e-06	9.45e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—STK11—pancreatic cancer	5.62e-06	9.3e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—pancreatic cancer	5.46e-06	9.04e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CB—pancreatic cancer	5.38e-06	8.91e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—pancreatic cancer	5.33e-06	8.83e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CD44—pancreatic cancer	5.33e-06	8.82e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.28e-06	8.73e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.22e-06	8.64e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.17e-06	8.56e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GCG—pancreatic cancer	5.11e-06	8.46e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMS—pancreatic cancer	4.83e-06	8e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—pancreatic cancer	4.82e-06	7.98e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—STK11—pancreatic cancer	4.8e-06	7.95e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—pancreatic cancer	4.65e-06	7.7e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.51e-06	7.46e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMS—pancreatic cancer	4.13e-06	6.84e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOE—pancreatic cancer	3.93e-06	6.51e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.72e-06	6.16e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	3.55e-06	5.87e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—pancreatic cancer	3.42e-06	5.67e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOE—pancreatic cancer	3.36e-06	5.56e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—pancreatic cancer	3.28e-06	5.43e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.18e-06	5.26e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	3.12e-06	5.16e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.03e-06	5.02e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—pancreatic cancer	2.93e-06	4.84e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	2.72e-06	4.5e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—pancreatic cancer	2.69e-06	4.46e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—pancreatic cancer	2.68e-06	4.44e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	2.67e-06	4.41e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—pancreatic cancer	2.35e-06	3.89e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.32e-06	3.85e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.3e-06	3.81e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.01e-06	3.32e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.66e-06	2.74e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.42e-06	2.34e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.35e-06	2.24e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.16e-06	1.92e-05	CbGpPWpGaD
